IL17A and Crohn disease: Complete blockage of IL-17A failed to ameliorate intestinal inflammation in Crohn's disease, which might be explained by preventing the beneficial actions of IL-17A, such as promotion of AMP production that ultimately protects the host against invading microbes (30).